1.6

How Do AI Platforms Work?

BenevolentBio, a London-based start-up, has developed its own AI platform. The

platform receives data from various sources (clinical trials, patient records, patents,

research papers, etc.). A representation of billions of known and drawn-out

relationships between biological entities, such as genes, proteins, species, tissues,

symptoms, diseases, and candidate drugs, is designed using the cloud. Such infor-

mation can be used to learn more about how a gene is linked to a specific medical

condition and which compounds can be used to treat it. As a result, AI will bring all

of this evidence into perspective and provide the essential information to drug-

development scientists (Fleming 2018). In silico development of new compounds

with desired activity has been made possible due to artificial intelligence. When AI is

Fig. 1.1 Precision medicines can be benefitted by “omics technologies” by identifying new disease

biomarkers, for diagnostics, prognosis, patient stratification, and drug development as well as

repurposing

8

R. C. Sobti et al.